SCHEMBL3320951

SCHEMBL3320951

Cc1ccc(-n2nccc2C(N)C(C)C)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.38
ALDH1A1 P00352 4/20 0.38
ATM Q13315 1/20 0.38
NPC1 O15118 6/20 0.38
RAB9A P51151 6/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
CYP2C9 P11712 4/20 0.38
CYP2C19 P33261 4/20 0.38
KMT2A Q03164 3/20 0.38
TP53 P04637 2/20 0.38
MEN1 O00255 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
POLB P06746 1/20 0.37
CYP2C18 P33260 2/20 0.37
NR3C2 P08235 1/20 0.36
LMNA P02545 4/20 0.36
STAT1 P42224 1/20 0.36
TSHR P16473 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3316602 0.85 MAPK14 (0.37) ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL3318897 0.81 ALDH1A1 (0.48) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3320565 0.80 ALDH1A1 (0.38) MAPTALDH1A1ATMNPC1RAB9A
SCHEMBL1491115 0.71 POLB (0.64) MAPTALDH1A1ATMNPC1RAB9A
SCHEMBL23130273 0.70 CYP2C9 (0.49) MAPTALDH1A1ATMNPC1RAB9A
SCHEMBL3318194 0.69 POLB (0.47) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4872919 0.68 MAPT (0.45) MAPTALDH1A1ATMNPC1RAB9A
SCHEMBL5732530 0.68 ALDH1A1 (0.42) MAPTALDH1A1ATMNPC1RAB9A
SCHEMBL5732531 0.68 ALDH1A1 (0.42) MAPTALDH1A1ATMNPC1RAB9A
SCHEMBL19443416 0.67 ALDH1A1 (0.44) MAPTALDH1A1ATMNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole WYETH LLP (US) 2010-06-10 US disclosed
US-7674813-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2010-03-09 US disclosed
EP-1709003-B1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH CORP (US) 2009-09-23 EP disclosed
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2008-10-09 US disclosed
US-7399778-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2008-07-15 US disclosed
EP-1709003-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE Wyeth (US) 2006-10-11 EP disclosed
WO-2005073198-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2005-08-11 WO disclosed
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole WYETH (US) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole APP, IAPP, PARK7 MAPT 524/4885ALDH1A1 4118/4885ATM 2429/4885
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE APP, IAPP, PARK7 MAPT 524/4885ALDH1A1 4118/4885ATM 2429/4885
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole IAPP, APP, CBR3 MAPT 1135/4885ALDH1A1 3920/4885ATM 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.